AN2 Therapeutics, Inc. ANTX
4.88
(0.01)
(0.20%)
as of 25 Sep
- Market cap
- $184.5M
- P/E
- 0.0×
Follow ANTX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(45.91%) | (52.14%) | (44.56%) | (50.12%) | |
| (41.21%) | (45.67%) | (40.93%) | (46.06%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(59.46%) | (68.68%) | (42.17%) | (48.75%) | |
Free Cash Flow per Share |
(0.99) | (0.99) | (0.92) | (0.69) | |
Free Cash Flow |
(29.87) | (29.83) | (31.28) | (30.68) | |
| Other line items | |||||
Cash ROIC |
(24.42%) | (26.86%) | (18.73%) | (19.88%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.85 | 0.91 | 0.85 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.99) | (0.99) | (0.92) | (0.69) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates